News
Sarepta Therapeutics hired a Trump-connected lobbying firm after the death of a teenage boy treated with its Duchenne ...
Novartis has made a takeover approach for rare disease-focused biotech Avidity Biosciences, as Big Pharma continues to hunt ...
Trump appeared to acknowledge in the interview that his ruthless mass deportation campaign is hurting farms, which rely on ...
As Laura Loomer wields a terrifying amount of power, other far-right influencers are accusing her of being a “plant.” ...
Jeffrey Epstein’s convicted accomplice revealed something interesting about her communication with the Trump administration.
I do not work for Big Pharma. I work in support of President Trump on the outside of the administration,’ Loomer tells The ...
1d
The New Republic on MSNLaura Loomer’s New Influence Is Already Backfiring on HerLaura Loomer’s conspiratorial followers are already cannibalizing her for participating in “the swamp.” Just a day after reports emerged that Defense Secretary Pete Hegseth had tapped the far-right “9 ...
The FDA is allowing Sarepta to resume shipments of Elevidys (delandistrogene moxeparvovec) to ambulatory patients with Duchenne muscular dystrophy.
From innovation in manufacturing to more-flexible regulation and better communication with payers, much needs to happen to ...
Sarepta and Capricor learned of key regulatory decisions from the media and investors, and Duchenne muscular dystrophy ...
Vinay Prasad, a professor who until earlier this year headed a cancer-drugs and health-policy lab at UC San Francisco, ...
Vinay Prasad's interim replacement has concerns about same drug that drove him out. NIH director says employee critics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results